BSE - Delayed Quote INR

OneSource Specialty Pharma Limited (ONESOURCE.BO)

1,591.75
+6.45
+(0.41%)
At close: May 12 at 3:29:12 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
Total Revenue
14,448,530
14,448,530
1,719,190
387,140
Cost of Revenue
4,350,340
4,350,340
705,090
204,110
Gross Profit
10,098,190
10,098,190
1,014,100
183,030
Operating Expense
8,171,900
8,171,900
2,659,420
2,341,850
Operating Income
1,926,290
1,926,290
-1,645,320
-2,158,820
Net Non Operating Interest Income Expense
-1,663,240
-1,663,240
-894,480
-459,660
Pretax Income
-670,660
-670,660
-3,656,970
-4,156,450
Tax Provision
-497,850
-497,850
0
0
Net Income Common Stockholders
-179,710
-179,710
-3,911,650
-7,998,300
Diluted NI Available to Com Stockholders
-179,710
-179,710
-3,911,650
-7,998,300
Basic EPS
-1.63
-1.63
-94.15
-192.51
Diluted EPS
-1.63
-1.63
-94.15
-192.51
Basic Average Shares
110,251.53
110,251.53
41,547
41,547
Diluted Average Shares
110,251.53
110,251.53
41,547
41,547
Rent Expense Supplemental
--
--
26,850
10,840
Total Expenses
12,522,240
12,522,240
3,364,510
2,545,960
Net Income from Continuing & Discontinued Operation
-179,710
-179,710
-3,911,650
-7,998,300
Normalized Income
492,260
492,260
-2,497,550
-2,708,920
Interest Income
--
--
19,170
15,790
Interest Expense
1,663,240
1,663,240
894,480
401,060
Net Interest Income
-1,663,240
-1,663,240
-894,480
-459,660
EBIT
992,580
992,580
-2,762,490
-3,755,390
EBITDA
3,731,420
3,731,420
-1,808,690
-2,614,380
Reconciled Cost of Revenue
4,350,340
4,350,340
705,090
204,110
Reconciled Depreciation
2,738,840
2,738,840
953,800
1,141,010
Net Income from Continuing Operation Net Minority Interest
-172,810
-172,810
-3,656,970
-4,156,450
Total Unusual Items Excluding Goodwill
-1,108,450
-1,108,450
-1,159,420
-1,447,530
Total Unusual Items
-1,108,450
-1,108,450
-1,159,420
-1,447,530
Normalized EBITDA
4,839,870
4,839,870
-649,270
-1,166,850
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
-443,380
-443,380
0
0
3/31/2023 - 1/24/2025

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NWRN.SW Newron Pharmaceuticals S.p.A.
8.20
-0.49%
 
KLRS Kalaris Therapeutics, Inc.
3.3800
-2.87%
 
BIOCON.NS Biocon Limited
328.15
-0.53%
 
YMAB Y-mAbs Therapeutics, Inc.
4.0700
+4.63%
 
ALXO ALX Oncology Holdings Inc.
0.4352
+3.05%
 
RPRX Royalty Pharma plc
33.35
+0.60%